We report the utility of rapid antigen tests (RAgT) in a cohort of US healthcare personnel with COVID-19 infection who met symptom criteria to return to work at day 5 or later of isolation. 11.9% of ...initial RAgT were negative. RAgT can be helpful to guide return to work decisions.
In a large cohort of US healthcare personnel (HCP) without prior COVID-19 infection, 94,382 doses of mRNA COVID-19 vaccine were administered to 49,220 individuals. The adjusted vaccine effectiveness ...following two doses of each of the two available brands of mRNA vaccine exceeded 96%.
COVID-19 vaccines are effective, but breakthrough infections have been increasingly reported. We conducted a test-negative case-control study to assess the durability of protection against ...symptomatic infection after vaccination with mRNA-1273. We fit conditional logistic regression (CLR) models stratified on residential county and calendar date of SARS-CoV-2 PCR testing to assess the association between the time elapsed since vaccination and the odds of symptomatic infection, adjusted for several covariates. There were 2,364 symptomatic individuals who had a positive SARS-CoV-2 PCR test after full vaccination with mRNA-1273 ("cases") and 12,949 symptomatic individuals who contributed 15,087 negative tests after full vaccination ("controls"). The odds of symptomatic infection were significantly higher 250 days after full vaccination compared to the date of full vaccination (Odds Ratio OR: 2.47, 95% confidence interval CI: 1.19-5.13). The odds of non-COVID-19 associated hospitalization and non-COVID-19 pneumonia (negative control outcomes) remained relatively stable over the same time interval (Day 250 OR
: 0.68, 95% CI: 0.47-1.0; Day 250 OR
: 1.11, 95% CI: 0.24-5.2). The odds of symptomatic infection remained significantly lower almost 300 days after the first mRNA-1273 dose as compared to 4 days after the first dose, when immune protection approximates the unvaccinated state (OR: 0.26, 95% CI: 0.17-0.39). Low rates of COVID-19 associated hospitalization or death in this cohort precluded analyses of these severe outcomes. In summary, mRNA-1273 robustly protected against symptomatic SARS-CoV-2 infection at least 8 months after full vaccination, but the degree of protection waned over this time period.
PDF
